This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What's in the Cards for Arena (ARNA) This Earnings Season?
by Zacks Equity Research
Although Arena's (ARNA) only approved product, Belviq, puts up a dismal show so far, the company's efforts to improve the drug's performance might drive the stock in Q1.
What's in the Cards for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) earns $30 million in license payments from AstraZeneca. Spinraza witnesses strong first quarter as announced by Biogen in its earnings release.
GW Pharma (GWPH) Q2 Earnings: Is a Turnaround in the Cards?
by Zacks Equity Research
GW Pharma (GWPH) is expected to report its fiscal second-quarter results next week. Investors focus is expected to be on commercialization plan for Epidiolex.
What's in Store for Intercept (ICPT) This Earnings Season?
by Zacks Equity Research
Investors are expected to focus on Ocaliva sales when Intercept (ICPT) reports first-quarter results (expected on May 3).
Zoetis (ZTS) Gears Up for Q1 Earnings: What's in Store?
by Zacks Equity Research
Zoetis' (ZTS) top line in the first quarter is likely to be driven by continued demand for dermatology portfolio and product launches.
AVEO Pharmaceuticals (AVEO) Q1 Earnings: What's in Store?
by Zacks Equity Research
AVEO Pharmaceuticals' (AVEO) first drug, Fotivda for the first-line treatment of RCC is likely to have a favorable impact on first-quarter results.
Zacks.com highlights: Illumina, Alarm.com Holdings, Copart and Vanda Pharmaceuticals
by Zacks Equity Research
Zacks.com highlights: Illumina, Alarm.com Holdings, Copart and Vanda Pharmaceuticals
4 Top Efficient Stocks to Buy for Stellar Returns
by Tirthankar Chakraborty
A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with its price performance.
Vanda Pharmaceuticals Inc. (VNDA) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Vanda Pharmaceuticals Inc. (VNDA) Sees Hammer Chart Pattern: Time to Buy?
bluebird bio (BLUE) Looks Good: Stock Adds 11% in Session
by Zacks Equity Research
bluebird bio (BLUE) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.
Looking for a Top Momentum Stock? 3 Reasons Why Vanda Pharmaceuticals (VNDA) is a Great Choice
by Zacks Equity Research
Vanda Pharmaceuticals (VNDA) stock is looking quite impressive now for momentum-oriented investors.
Zacks.com featured highlights Sanderson Farm, Heska Corp, Vanda Pharmaceuticals Lantheus and NVR
by Zacks Equity Research
Zacks.com featured highlights Sanderson Farm, Heska Corp, Vanda Pharmaceuticals Lantheus and NVR
Strength Seen in Vascular Biogenics (VBLT): Stock Jumps 5.3%
by Zacks Equity Research
Vascular Biogenics (VBLT) shares rose over 5% in the last trading session.
Vanda Pharmaceuticals (VNDA) Worth a Look: Stock Jumps 8%
by Zacks Equity Research
Vanda Pharmaceuticals Inc. (VNDA) shares rose over 8% in the last trading session.
Merck KGaA Expands Distribution Deal with Roche (revised)
by Zacks Equity Research
Germany-based Merck KGaA announced that it has expanded the distribution alliance with Roche Holding AG (RHHBY).
Abbott Labs to Close St. Jude Acquisition Later this Week
by Zacks Equity Research
Abbott Laboratories (ABT) announced to close the acquisition of St. Jude Medical, Inc., (STJ) on Jan 4, 2017.
Immunomedics Completes Enrollment In Cancer Drug Study
by Zacks Equity Research
Immunomedics (IMMU) achieved the planned enrollment in a phase II study on IMMU-132.
Cempra (CEMP) Gets CRL from FDA for Pneumonia Candidate
by Zacks Equity Research
Cempra (CEMP) announced that it received a CRL from the FDA relating to its new drug applications for oral and intravenous formulation of candidate solithromycin.
Prima (PBMD) Reports Favorable Initial Melanoma Study Data
by Zacks Equity Research
Prima (PBMD) announced interim data from the TACTI-mel program on IMP321 for the treatment of patients with unresectable or metastatic melanoma.
Innocoll (INNL) Down on FDA's Refusal to File Xaracoll NDA
by Zacks Equity Research
Innocoll (INNL) announced that it has received a Refusal to File letter from the FDA in connection with the NDA for Xaracoll for the treatment of postsurgical pain.
Abbott to Sell 2 Medical Device Businesses for St. Jude Buyout
by Zacks Equity Research
Abbott Laboratories (ABT) has agreed to divest two medical device businesses in order to settle Federal Trade Commission (FTC) charges in relation to its proposed acquisition of St. Jude Medical (STJ).
ImmunoGen: Phase I Data on Ovarian Cancer Drug Published
by Zacks Equity Research
ImmunoGen, Inc. (IMGN) announced that data from a 46-patient phase I expansion cohort study on its lead pipeline candidate, mirvetuximab soravtansine (IMGN853), were published in the Journal of Clinical Oncology.
BioMarin (BMRN) Raised to Buy: Should You Add the Stock?
by Zacks Equity Research
The Zacks Investment Research upgraded BioMarin (BMRN) to a Zacks #2 Rank (Buy).
Galena Biopharma Reveals Regulatory Pathway for GALE-401
by Zacks Equity Research
Galena (GALE) confirmed the regulatory pathway to advance GALE-401 (anagrelide CR) into a pivotal phase III study.
Amphastar Stock Down on CRL for Asthma Drug in the U.S.
by Zacks Equity Research
Amphastar Pharmaceuticals, Inc. (AMPH) announced that its subsidiary, Armstrong Pharmaceuticals, Inc., has received a Complete Response Letter (CRL) from the FDA for Primatene Mist (epinephrine inhalation aerosol).